Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 37,300 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

37,300 Papers indexed
371 Papers AI scored
37,300 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

37300 results
B
AI -
Base 74.4
Rank 74.4
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.4/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 22.0; sample size: 30.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Base 74.4
Rank 74.4
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.4/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 42.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Base 74.4
Rank 74.4
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.4/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 52.0; sample size: 50.0; recency: 100.0; abstract quality: 100.0.

B
Management outcomes of prolactinoma: a retrospective study from Southern Iraq.
PMID 41178903 Published: 2025-09-01 Ingested: 2026-08-02 12:05 AM Journal of medicine and life
AI -
Base 74.4
Rank 74.4
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.4/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 42.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.

B
Asparaginase Premedication With Hydrocortisone Decreases Hypersensitivity Reactions.
PMID 40928245 Published: 2025-09-10 Ingested: 2026-08-02 12:05 AM Journal of pediatric hematology/oncology
AI -
Base 74.4
Rank 74.4
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.4/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 52.0; sample size: 50.0; recency: 100.0; abstract quality: 100.0.

B
Life Milestone Achievement Among Young Adult Childhood Cancer Survivors: A Population-Based Cohort and Matched Case-Control Study.
PMID 40827033 Published: 2025-08-18 Ingested: 2026-08-02 12:04 AM Pediatric blood & cancer
AI -
Base 74.4
Rank 74.4
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.4/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 32.0; sample size: 90.0; recency: 100.0; abstract quality: 100.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.4/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 52.0; sample size: 60.0; recency: 90.0; abstract quality: 100.0.

Previous
Page 320 of 3109
Next
Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic